Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Radioimmunodetection of melanoma utilizing In-111 96. 5 monoclonal antibody: A preliminary report

Conference · · Radiology; (United States)
OSTI ID:5612418

The murine 96.5 monoclonal antimelanoma antibody (MoAb) was labeled with In-111, and 1-20 mg were administered to 21 patients who had proved or suspected melanoma metastases. In four patients, unlabeled 96.5 MoAb was administered prior to the radiopharmaceutical. The scans were interpreted by two observers, one with full knowledge, the other with no knowledge of the cases. Increasing the MoAb mass or preinfusing unlabeled MoAb prior to the administration of In-111 MoAb resulted in a prolongation of In-111 MoAb of the serum half time, and appeared to improve tumor detection. In all patients who had metastatic disease, at least one tumor site was apparent. Fifty-six per cent of known lesions 1.5 cm or greater in size were detected by the physician who had knowledge of the cases when data from all doses were considered. Forty-nine per cent were detected by the other physician. The 96.5 In-111 MoAb appears to have utility for the detection of metastatic melanoma.

Research Organization:
Univ. of California, San Diego
OSTI ID:
5612418
Report Number(s):
CONF-851152-
Journal Information:
Radiology; (United States), Journal Name: Radiology; (United States) Vol. 155:2; ISSN RADLA
Country of Publication:
United States
Language:
English